Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study

Published:2024-05 Issue: Volume:203 Page:114039
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Tuninetti Valentina,Virano Elisa,Salutari Vanda,Ricotti Andrea,Pisano Carmela,Ducceschi Monika,Turitto Giacinto,Scandurra Giuseppa,Petrella Maria Cristina,Forestieri Valeria,Rizzetto Monica,Mammoliti Serafina,Artioli Grazia,Cioffi Raffaella,Borsotti Lucia,Bellero Marco,Rognone Chiara,Carbone Vittoria,Ferrandina Gabriella,Mantiero Mara,Azzolina Carmen,Geninatti Eleonora,Pignata Sandro,Valabrega Giorgio

Funder

University of Turin

Publisher

Elsevier BV

Reference29 articles.

1. Systemic therapy in cervical cancer: 30 years in review;Liontos;Crit Rev Oncol Hematol,2019

2. Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms;Mori;J Hum Genet,2021

3. Recurrent or primary metastatic cervical cancer: current and future treatments;Gennigens;ESMO Open,2022

4. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer;Colombo;N Engl J Med,2021

5. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study;Chung;J Clin Oncol,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP